Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) have been given a consensus recommendation of “Moderate Buy” by the five research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $34.3333.

A number of equities analysts have recently weighed in on the company. Westpark Capital started coverage on Unicycive Therapeutics in a report on Thursday, February 19th. They issued a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Monday, December 29th.

Unicycive Therapeutics Stock Performance

UNCY stock opened at $6.73 on Monday. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $11.00. The stock’s 50 day moving average price is $6.63 and its 200 day moving average price is $5.66. The firm has a market cap of $144.63 million, a P/E ratio of -1.70 and a beta of 1.82.

Institutional Investors Weigh In On Unicycive Therapeutics

Several hedge funds have recently modified their holdings of the company. Lazard Asset Management LLC purchased a new stake in shares of Unicycive Therapeutics during the second quarter worth about $55,000. JPMorgan Chase & Co. lifted its stake in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after buying an additional 21,525 shares during the period. Citadel Advisors LLC acquired a new stake in Unicycive Therapeutics during the third quarter worth approximately $182,000. Quadrature Capital Ltd acquired a new stake in Unicycive Therapeutics during the fourth quarter worth approximately $226,000. Finally, State Street Corp grew its stake in Unicycive Therapeutics by 19.0% in the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after acquiring an additional 10,400 shares during the period. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.